A detailed history of Larson Financial Group LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Larson Financial Group LLC holds 92 shares of PCVX stock, worth $4,447. This represents 0.0% of its overall portfolio holdings.

Number of Shares
92
Holding current value
$4,447
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$29.67 - $37.37 $2,729 - $3,438
92 New
92 $3,000
Q1 2025

May 02, 2025

BUY
$37.76 - $92.13 $528 - $1,289
14 New
14 $0

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $2.87B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Larson Financial Group LLC Portfolio

Follow Larson Financial Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Larson Financial Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Larson Financial Group LLC with notifications on news.